Vaping devices, or electronic cigarettes, mimic traditional smoking by heating a liquid into vapor rather than burning tobacco. Unlike cigarettes, they produce no carbon monoxide and offer adjustable nicotine levels, including zero-nicotine options. Emerging research positions them as a valuable tool for smoking cessation.
Opinions on e-cigarettes remain mixed among health experts. In November, France's High Council for Public Health affirmed their role in helping smokers quit or cut back on tobacco, while cautioning they may attract non-smokers, especially youth drawn to appealing flavors.
The World Health Organization echoes concerns that young e-cigarette users are up to three times more likely to try tobacco later. Yet, the National Cancer Institute notes that key carcinogens and cardiovascular toxins from tobacco are minimal or absent in e-cigarette vapor. While long-term effects require more study, evidence supports e-cigarettes for quitting, particularly among pregnant women.
Pregnant smokers are often advised nicotine patches to protect fetal health—smoking raises risks of miscarriage, preterm birth, and sudden infant death syndrome. However, patches show limited success in this group.
Prior trials tested nicotine replacement therapy (NRT) and bupropion against placebos. NRT had modest effects (nicotine metabolizes faster in pregnancy, potentially under-dosing), while bupropion proved ineffective.
Researchers at London's Wolfson Institute of Population Health compared e-cigarettes to patches. E-cigarettes offer customizable nicotine, enjoyable flavors, and the familiar hand-to-mouth ritual, enhancing adherence.
The study enrolled 1,140 pregnant smokers (averaging 10 cigarettes daily at 15.7 weeks gestation) from 24 UK hospitals. Half received patches; half got e-cigarettes.
Prolonged abstinence rates (verified by end-of-pregnancy saliva tests) were similar initially, but some patch users switched to vaping. Adjusted rates: 6.8% for e-cigarettes vs. 3.6% for patches. Self-reported abstinence: 19.8% vs. 9.7%.
Birth outcomes were comparable, except lower low-birth-weight incidence (<2.5 kg) in the e-cigarette group (9.8% vs. 14.8%). Researchers stress: ideally, quit without nicotine. But between e-cigarettes and continued smoking, vaping is preferable.
A Cochrane review of 61 studies found moderate evidence e-cigarettes boost quit rates over other aids, with no serious side effects—throat/mouth irritation most common short-term.
On gateway risks, France's Constances cohort (8,042 non-smokers) found exclusive vaping rare (11 cases), with none progressing to smoking after one year. E-cigarettes appear to aid quitting, not initiate it.
